Bripca 50mg Tablet
Marketer
Ipca Laboratories Ltd
Salt Composition
Brivaracetam (50mg)
Overview Bripca 50mg Tablet
Epileptic seizures are managed with the anticonvulsant Bripca 50mg tablets. This medication, used alone or in conjunction with other treatments, controls seizure activity through suppression of abnormal brain electrical impulses. Consistent daily dosing, at the same time each day for optimal effect, is crucial, regardless of food intake. Dosage frequency and strength are determined individually by your physician to effectively manage your seizures, with potential gradual increases. Long-term use is typical; discontinuation should only occur under your doctor's guidance as abrupt cessation may worsen seizures. Continue taking Bripca 50mg as prescribed, even if feeling well. Common side effects, often diminishing after initial weeks, include nausea, vomiting, headache, and dizziness. Behavioral changes like irritability, aggression, or agitation are also possible. While most side effects are mild, some necessitate medical attention. Suicidal ideation has been reported in a small percentage of patients; report any worsening mood immediately to your physician. Prior to commencing treatment, inform your physician of any pre-existing liver or kidney disease, depression, suicidal thoughts, pregnancy, or breastfeeding plans. Consult your doctor before using Bripca 50mg if you are breastfeeding.
Primary Ingredients of Bripca 50mg Tablet
No text provided to rephrase.
Uses of Bripca 50mg Tablet
Convulsive disorders
Major Benefits of Bripca 50mg Tablet:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the tablet whole; avoid chewing, crushing, or breaking it. Bripca 50mg Tablets can be consumed with or without food, though consistent timing is recommended.
Common Side effects of Bripca 50mg Tablet:
- Behavioral changes
- Agitation
- Aggressive behavior
- Dizziness
- Sedation
- Drowsiness
- Neuropsychiatric symptoms
How to use Bripca 50mg Tablet:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the 50mg Bripca tablet whole; avoid chewing, crushing, or fracturing it. Consumption may coincide with meals or be taken independently, though consistent timing is recommended.
How Bripca 50mg Tablet works:
Levetiracetam 50mg tablets are used to control epileptic seizures. Their mechanism involves binding to synaptic vesicle protein 2A (SV2A) receptors on neurons. This action reduces excessive neuronal firing in the brain, thereby preventing the propagation of seizure-inducing electrical impulses.
SAFETY ADVICE
AlcoholUNSAFE
Combining Bripca 50mg Tablet and alcohol is inadvisable.
PregnancyCONSULT YOUR DOCTOR
The use of Bripca 50mg tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible risks prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Data on the safety of Bripca 50mg Tablet while breastfeeding is lacking. Seek medical advice from your physician.
DrivingUNSAFE
Taking a Bripca 50mg tablet may cause drowsiness, blurred vision, and dizziness, reducing alertness. Driving should be avoided if these effects are experienced.
KidneySAFE IF PRESCRIBED
For individuals with kidney impairment, Bripca 50mg Tablet is considered safe, and no dosage modification is advised. However, its use is not recommended for those with end-stage renal disease, given the absence of supporting clinical trial data.
LiverCAUTION
Individuals with hepatic impairment should use Bripca 50mg tablets cautiously; dosage modification may be necessary. Physician consultation is advised.
What if you forget to take Bripca 50mg Tablet :
NA
Facts to Know About Bripca 50mg Tablet
| Label | Value |
|---|---|
| Chemical Category | Levetiracetam Analog |
| Developing Habits | No. |
| Treatment Category | Neuroscience Central Nervous System |
| Action Class | AED: A protein ligand within synaptic vesicle 2 |





